- Home
- PRPL vs FBRX Comparison
PRPL vs FBRX Comparison
Compare PRPL & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRPL
- FBRX
- Stock Information
- Founded
- PRPL 2010
- FBRX N/A
- Country
- PRPL United States
- FBRX United States
- Employees
- PRPL N/A
- FBRX N/A
- Industry
- PRPL Home Furnishings
- FBRX Biotechnology: Pharmaceutical Preparations
- Sector
- PRPL Consumer Discretionary
- FBRX Health Care
- Exchange
- PRPL Nasdaq
- FBRX Nasdaq
- Market Cap
- PRPL 96.8M
- FBRX 80.6M
- IPO Year
- PRPL N/A
- FBRX N/A
- Fundamental
- Price
- PRPL $0.71
- FBRX $12.53
- Analyst Decision
- PRPL Hold
- FBRX Strong Buy
- Analyst Count
- PRPL 2
- FBRX 2
- Target Price
- PRPL $1.25
- FBRX $61.00
- AVG Volume (30 Days)
- PRPL 302.5K
- FBRX 75.1K
- Earning Date
- PRPL 08-04-2025
- FBRX 08-13-2025
- Dividend Yield
- PRPL N/A
- FBRX N/A
- EPS Growth
- PRPL N/A
- FBRX N/A
- EPS
- PRPL N/A
- FBRX N/A
- Revenue
- PRPL $472,015,000.00
- FBRX N/A
- Revenue This Year
- PRPL N/A
- FBRX N/A
- Revenue Next Year
- PRPL $10.65
- FBRX N/A
- P/E Ratio
- PRPL N/A
- FBRX N/A
- Revenue Growth
- PRPL N/A
- FBRX N/A
- 52 Week Low
- PRPL $0.56
- FBRX $4.11
- 52 Week High
- PRPL $1.50
- FBRX $28.68
- Technical
- Relative Strength Index (RSI)
- PRPL 40.57
- FBRX 63.13
- Support Level
- PRPL $0.70
- FBRX $11.36
- Resistance Level
- PRPL $0.75
- FBRX $13.74
- Average True Range (ATR)
- PRPL 0.04
- FBRX 0.94
- MACD
- PRPL -0.01
- FBRX 0.09
- Stochastic Oscillator
- PRPL 6.15
- FBRX 77.68
About PRPL Purple Innovation Inc.
Purple Innovation Inc is a comfort innovation company. The company designs, manufactures and sells a range of comfort technology offerings, including mattresses, a pillow, cushions, sheets, bed platforms, and other products. It sells its products through online channels, traditional wholesale partners and third-party online retailers.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).